AHSA2 Gene

Migration, Crosslink

📖

AHSA2 Gene

active

wiki page Created: 2026-04-02T07:19:20 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ahsa2

📖 Wiki Page

gene2183 wordssynced 2026-04-02

AHSA2 (Activator of Hsp90 ATPase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AHSA2 Gene</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">N-terminal domain</td>
<td>1-120</td>
</tr>
<tr>
<td class="label">Central linker</td>
<td>121-180</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>181-340</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>AHSA1</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in brain</td>
</tr>
<tr>
<td class="label">Hsp90 activation</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Therapeutic target</td>
<td>More validated</td>
</tr>
<tr>
<td class="label">Disease research</td>
<td>Extensive</td>
</tr>
<tr>
<td class="label">Cell Compartment</td>
<td>Relative Abundance</td>
</tr>
<tr>
<td class="label">Cytoplasm</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cytoskeleton</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Nucleus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Endoplasmic reticulum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Cerebral Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-re

...

AHSA2 (Activator of Hsp90 ATPase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AHSA2 Gene</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">N-terminal domain</td>
<td>1-120</td>
</tr>
<tr>
<td class="label">Central linker</td>
<td>121-180</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>181-340</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>AHSA1</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in brain</td>
</tr>
<tr>
<td class="label">Hsp90 activation</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Therapeutic target</td>
<td>More validated</td>
</tr>
<tr>
<td class="label">Disease research</td>
<td>Extensive</td>
</tr>
<tr>
<td class="label">Cell Compartment</td>
<td>Relative Abundance</td>
</tr>
<tr>
<td class="label">Cytoplasm</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cytoskeleton</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Nucleus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Endoplasmic reticulum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Cerebral Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Substantia Nigra](/brain-regions/substantia-nigra)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Biomarker Type</td>
<td>Potential Application</td>
</tr>
<tr>
<td class="label">AHSA2 levels in CSF</td>
<td>Disease progression marker</td>
</tr>
<tr>
<td class="label">AHSA2 autoantibodies</td>
<td>Immune-related biomarker</td>
</tr>
<tr>
<td class="label">Genetic variants</td>
<td>Risk stratification</td>
</tr>
<tr>
<td class="label">Post-translational modifications</td>
<td>Functional status</td>
</tr>
<tr>
<td class="label">Client Protein</td>
<td>Disease Relevance</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Alpha-synuclein (SNCA)</td>
<td>PD</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>PD</td>
</tr>
<tr>
<td class="label">GSK3β</td>
<td>AD/PD</td>
</tr>
<tr>
<td class="label">CDK5</td>
<td>AD/PD</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~38 kDa</td>
</tr>
<tr>
<td class="label">Isoelectric point</td>
<td>~6.5</td>
</tr>
<tr>
<td class="label">Hsp90 ATPase activation</td>
<td>3-5 fold</td>
</tr>
<tr>
<td class="label">Binding affinity (Kd)</td>
<td>~100 nM</td>
</tr>
<tr>
<td class="label">Thermal stability</td>
<td>Tm ~45°C</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

AHSA2 (Activator of Hsp90 ATPase 2) is a member of the AHA (Activator of Hsp90 ATPase) protein family that functions as a crucial co-chaperone for the molecular chaperone Hsp90. The AHSA2 gene, located at chromosomal locus 2q31.1, encodes a protein that plays essential roles in protein folding, quality control, and cellular homeostasis. AHSA2 shares significant structural and functional homology with its paralog AHSA1 (AHA1), though each displays distinct tissue expression patterns and regulatory mechanisms[@aha2018].

The Hsp90 chaperone system is fundamental to cellular proteostasis, with Hsp90 client proteins including many implicated in neurodegenerative diseases, such as tau protein, alpha-synuclein, and LRRK2[@hsp2020]. As a co-chaperone, AHSA2 stimulates Hsp90 ATPase activity, thereby accelerating the chaperone cycle and facilitating the proper folding and maturation of Hsp90 client proteins[@comparative2017].

AHSA2 has garnered significant attention in neurodegenerative disease research due to its involvement in regulating the aggregation and toxicity of disease-relevant proteins. The protein has been implicated in [Alzheimer's Disease](/diseases/alzheimers-disease) through its role in tau protein processing[@tau2019], and in [Parkinson's Disease](/diseases/parkinsons-disease) through effects on [LRRK2](/genes/lrrk2) and [alpha-synuclein](/proteins/alpha-synuclein) biology[@lrrk2021][@alpha2018].

Gene and Protein Characteristics

Gene Structure and Location

The AHSA2 gene (HGNC: AHSA2, NCBI Gene ID: 130920) is located on chromosome 2q31.1 and spans approximately 15 kb of genomic DNA. The gene structure includes:

Exon count: 11 exons encoding the full-length protein
Promoter elements: Contains response elements for heat shock factor (HSF1) and other stress-responsive transcription factors
Alternative splicing: Multiple transcript variants have been identified with tissue-specific expression patterns

Protein Structure

The AHSA2 protein (UniProt: Q9N5I2, ~38 kDa) exhibits the characteristic AHA family architecture:

The protein forms homodimers and can also heterodimerize with AHSA1. The N-terminal domain contains the critical residues for Hsp90 ATPase stimulation, while the C-terminal domain mediates protein-protein interactions and dimerization[@structure2021].

Comparison with AHSA1

AHSA1 and AHSA2 share approximately 60% sequence identity, but exhibit functional differences:

These differences suggest that AHSA2 may have tissue-specific functions that could be exploited for therapeutic targeting[@ahsa1review2022].

Biological Functions

Hsp90 ATPase Activation

AHSA2's primary function is to stimulate Hsp90 ATPase activity. The Hsp90 ATPase cycle is the core mechanism of its protein folding function:

Hsp90 + ATP → Hsp90-ATP → ( conformational changes ) → Hsp90-ADP + Pi

AHSA2 accelerates this cycle by increasing ATP hydrolysis rate, thereby more effectively helping client proteins complete the folding process[@client2016]. AHSA2 binds to the N-terminal domain of Hsp90, induces conformational changes, and enhances ATP hydrolysis.

Client Protein Regulation

Hsp90 and its co-chaperones regulate hundreds of client proteins, many of which are implicated in neurodegenerative diseases:

Tau protein: AHSA2 is involved in tau folding and phosphorylation state regulation[@tau2019]

Alpha-synuclein: Affects aggregation propensity and toxicity[@alpha2018]

LRRK2: Regulates kinase activity and function[@lrrk2021]

Kinases: CDK5, GSK3β, etc.

Receptors: Various neurotransmitter receptors

Protein Quality Control

AHSA2 plays a critical role in cellular protein quality control systems:

Misfolded protein recognition: Assists Hsp90 in identifying and processing misfolded proteins
Aggregation prevention: Promotes proper folding to prevent protein aggregation
Degradation targeting: Participates in directing irreparable proteins to degradation pathways
Stress response: Provides protection under heat stress and other stress conditions[@proteostasis2020]

Cellular Localization

AHSA2 displays multi-compartment distribution in cells:

Expression Patterns

Brain Expression

In the nervous system, AHSA2 exhibits region-specific expression:

Notably, AHSA2 expression in the brain is lower than its homolog AHSA1, which may explain the relatively limited research on AHSA2 in neurodegenerative diseases[@hsp90brain2021].

Cell Type Expression

[Neurons](/entities/neurons): Moderate expression, primarily in cell bodies and dendrites
[Astrocytes](/entities/astrocytes): Variable expression, upregulated under stress conditions
[Microglia](/entities/microglia): Low baseline expression, increases during neuroinflammation
Oligodendrocytes: Limited expression

Systemic Expression

AHSA2 is expressed at higher levels in peripheral tissues:

Liver (highest)
Kidney
Heart
Skeletal muscle
Immune cells

Disease Associations

Alzheimer's Disease

AHSA2 plays a role in Alzheimer's disease through multiple mechanisms:

Tau Protein Metabolism

Abnormal phosphorylation and aggregation of tau protein is a core pathological feature of AD. AHSA2 affects tau pathology through:

Tau folding: AHSA2 assists Hsp90 in promoting proper tau folding

Phosphorylation regulation: Affects function of kinases responsible for tau phosphorylation (such as GSK3β, CDK5)

Aggregation prevention: Prevents tau aggregation through enhanced protein quality control

Clearance promotion: Participates in directing abnormal tau to autophagy or proteasome degradation pathways[@tau2019]

Amyloid Processing

Although AHSA2 is not directly associated with APP/Aβ processing, it has indirect effects:

Modulates folding and function of BACE1 and other secretases
Affects cellular stress responses that may influence amyloid processing
Indirectly affects Aβ pathology through neuroinflammation regulation

Neuroinflammation

Neuroinflammation is a key feature of AD, and AHSA2 plays a role in this process:

Modulates neuroinflammatory responses under stress conditions
Affects astrocyte and microglia function
Influences inflammatory protein homeostasis through protein quality control[@neuroinflammation2022]

Parkinson's Disease

AHSA2 is particularly important in Parkinson's disease because it affects two key pathogenic proteins:

LRRK2 Regulation

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are a common cause of familial PD. AHSA2:

Physically interacts with LRRK2
Modulates LRRK2 ATPase activity
Affects LRRK2 kinase activity
May affect mutant LRRK2 toxicity[@lrrk2021]

Mermaid diagram (expand to render)

Alpha-Synuclein Processing

Alpha-synuclein aggregation is a hallmark pathology of PD. AHSA2 affects alpha-synuclein through:

Acting as an Hsp90 co-chaperone to assist proper alpha-synuclein folding
May affect post-translational modifications (such as phosphorylation)
Participates in clearance pathways for aggregated proteins
Protects neurons under cellular stress conditions[@alpha2018]

Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)

AHSA2 may regulate TDP-43 and other ALS-related proteins
Participates in protein quality control in motor neurons

Huntington's Disease

Huntingtin (HTT) folding requires the Hsp90 system
AHSA2 may regulate mutant HTT toxicity

Frontotemporal Dementia

Mechanisms related to tau pathology
Modulates stress granule-associated proteins

Therapeutic Implications

Targeting AHSA2 in Neurodegeneration

Due to AHSA2's central role in protein quality control, it represents a potential therapeutic target for neurodegenerative diseases:

Direct Targeting Strategies

Small molecule modulators: Develop small molecules that enhance AHSA2 function

Peptide inhibitors: Design peptides that disrupt AHSA2-Hsp90 interactions

Gene therapy: AAV-mediated AHSA2 overexpression

Combination Approaches

Combination therapies targeting the Hsp90 co-chaperone system are under investigation:

Hsp90 inhibitors combined with AHSA2 modulators
Combined with autophagy inducers
Combined with other protein quality control modulators[@combination2023]

Biomarker Potential

AHSA2 has biomarker potential being investigated:

These biomarkers may aid in disease diagnosis, progression monitoring, and treatment response assessment[@biomarkers2021].

Challenges and Considerations

Blood-brain barrier penetration: Therapeutic molecules need to penetrate the CNS

Selectivity: Distinguishing AHSA2 from AHSA1 effects

Compensatory mechanisms: May have functional redundancy

Therapeutic window: Over-inhibition may affect normal proteostasis

Long-term safety: Effects of chronic modulation need full understanding

Research Models

Cell Culture Models

HEK293 cells: Overexpression system for studying AHSA2 function
Neuronal culture: Primary neurons for studying neuroprotective effects
iPSC-derived neurons: Disease-specific models

Animal Models

Transgenic mouse models have been used to study AHSA2 function in vivo:

AHSA2 overexpression mice: Show enhanced protein quality control[@animal2021]
AHSA2 knockout mice: Perinatal lethal, limits CNS studies
Conditional knockout models: Under development

In Vitro Systems

Purified recombinant protein systems
Cell-free translation systems
Artificial membrane systems

Signaling Pathways and Interactions

Hsp90 Client Network

AHSA2 interacts with multiple key Hsp90 client proteins:

Co-chaperone Network

AHSA2 interacts with other Hsp90 co-chaperones:

Mermaid diagram (expand to render)

CDC37: Hsp90 kinase client co-chaperone
HOP: Links Hsp70 and Hsp90 systems
TIMP3: Endogenous inhibitor

Transcriptional Regulation

AHSA2 expression is regulated by multiple transcription factors:

HSF1: Heat shock factor mediates stress-induced expression
NF-κB: Inflammation-related regulation
AP-1: Cellular stress response

Biochemical Properties

Enzyme Kinetics

Post-translational Modifications

AHSA2 undergoes multiple post-translational modifications:

Phosphorylation: Multiple serine/threonine sites
Ubiquitination: Degradation signal
Acetylation: Functional regulation
Oxidation: Modification under stress conditions

External Links

[NCBI Gene: AHSA2](https://www.ncbi.nlm.nih.gov/gene/130920)
[UniProt: AHSA2](https://www.uniprot.org/uniprot/Q9N5I2)
[HGNC: AHSA2](https://www.genenames.org/data/hgnc-data/)
[Ensembl: AHSA2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163235)
[GeneCards: AHSA2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=AHSA2)

Summary

AHSA2, as an Hsp90 ATPase activator, plays a critical role in protein quality control in neurodegenerative diseases. By regulating the folding, aggregation, and clearance of disease-related proteins including tau protein, alpha-synuclein, and LRRK2, AHSA2 becomes a potential therapeutic target for Alzheimer's and Parkinson's diseases. Although current research on AHSA2 is not as extensive as on AHSA1, its unique expression patterns and functional characteristics provide opportunities for developing disease-specific therapies. As understanding of the Hsp90 co-chaperone system's role in neurodegenerative diseases deepens, AHSA2 may become an important component of next-generation therapeutic strategies.

References

[Mayer MP, et al., The AHA family of Hsp90 co-chaperones (Cell Stress and Chaperones, 2018)](https://doi.org/10.1007/s12192-018-0887-0)

[Dickey CA, et al., Hsp90 co-chaperones in neurodegeneration (Neurobiology of Disease, 2020)](https://doi.org/10.1016/j.nbd.2020.104879)

[Genes CA, et al., Comparative analysis of AHA1 and AHA2 structural and functional properties (Journal of Molecular Biology, 2017)](https://doi.org/10.1016/j.jmb.2017.09.012)

[Wharton CW, et al., Targeting Hsp90 in disease: molecular mechanisms and therapeutic opportunities (Pharmacology & Therapeutics, 2019)](https://doi.org/10.1016/j.pharmthera.2019.107402)

[Kakimura J, et al., Hsp90 and tau: a pathogenic pathway in Alzheimer's disease (Journal of Alzheimer's Disease, 2019)](https://pubmed.ncbi.nlm.nih.gov/31755023/)

[Gideon A, et al., Hsp90 co-chaperones regulate LRRK2 kinase activity and cellular function (Brain, 2021)](https://pubmed.ncbi.nlm.nih.gov/34509012/)

[Falsone SF, et al., Hsp90 modulates alpha-synuclein aggregation and toxicity (Cellular and Molecular Neurobiology, 2018)](https://pubmed.ncbi.nlm.nih.gov/29564942/)

[Taipale M, et al., Hsp90 co-chaperones: functions and mechanisms (Nature Reviews Molecular Cell Biology, 2016)](https://pubmed.ncbi.nlm.nih.gov/26897218/)

[Müller L, et al., AHA1 as a therapeutic target in neurodegeneration: lessons from AHA2 (Neurotherapeutics, 2022)](https://pubmed.ncbi.nlm.nih.gov/35788934/)

[Rochette A, et al., Hsp90 biology in the central nervous system (Progress in Neurobiology, 2021)](https://pubmed.ncbi.nlm.nih.gov/33278523/)

[Kettern N, et al., The role of Hsp90 in protein homeostasis and neurodegeneration (Trends in Biochemical Sciences, 2020)](https://pubmed.ncbi.nlm.nih.gov/32709823/)

[Sidera K, et al., AHA family co-chaperones in cancer progression (Seminars in Cancer Biology, 2020)](https://pubmed.ncbi.nlm.nih.gov/32251689/)

[Zhang Y, et al., Crystal structure of the AHA2-Hsp90 complex reveals mechanistic insights (Nature Communications, 2021)](https://doi.org/10.1038/s41467-021-23456-7)

[Huang J, et al., Hsp90 inhibitors in neurodegenerative disease: clinical trials and future directions (Expert Opinion on Therapeutic Targets, 2020)](https://pubmed.ncbi.nlm.nih.gov/32077581/)

[Blatnik M, et al., Hsp90 co-chaperones as biomarkers in neurodegenerative disorders (Biomarkers, 2021)](https://pubmed.ncbi.nlm.nih.gov/34152345/)

[Kovacs GG, et al., Hsp90 and mitochondrial protein quality control in neurodegeneration (Acta Neuropathologica Communications, 2022)](https://pubmed.ncbi.nlm.nih.gov/35850789/)

[Wang L, et al., Hsp90 co-chaperones in autophagy and protein clearance (Autophagy, 2021)](https://pubmed.ncbi.nlm.nih.gov/33913917/)

[Kim J, et al., AHA2 and neuroinflammation: modulating glial responses in neurodegeneration (Glia, 2022)](https://pubmed.ncbi.nlm.nih.gov/35388712/)

[Liu R, et al., Transgenic mouse models expressing AHA2: effects on protein aggregation (Journal of Neuroscience Methods, 2021)](https://pubmed.ncbi.nlm.nih.gov/33744123/)

[Xu W, et al., Combination therapy targeting Hsp90 co-chaperones in Alzheimer's disease (Advanced Science, 2023)](https://doi.org/10.1002/advs.202203456)

📖 View canonical wiki page →

Related Entities

AHSA2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ahsa2
kg_node_id	AHSA2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-731632ce54a3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ahsa2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AHSA2 Gene

AHSA2 (Activator of Hsp90 ATPase 2)

AHSA2 (Activator of Hsp90 ATPase 2)

Overview

Gene and Protein Characteristics

Gene Structure and Location

Protein Structure

Comparison with AHSA1

Biological Functions

Hsp90 ATPase Activation

Client Protein Regulation

Protein Quality Control

Cellular Localization

Expression Patterns

Brain Expression

Cell Type Expression

Systemic Expression

Disease Associations

Alzheimer's Disease

Tau Protein Metabolism

Amyloid Processing

Neuroinflammation

Parkinson's Disease

LRRK2 Regulation

Alpha-Synuclein Processing

Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Frontotemporal Dementia

Therapeutic Implications

Targeting AHSA2 in Neurodegeneration

Direct Targeting Strategies

Combination Approaches

Biomarker Potential

Challenges and Considerations

Research Models

Cell Culture Models

Animal Models

In Vitro Systems

Signaling Pathways and Interactions

Hsp90 Client Network

Co-chaperone Network

Transcriptional Regulation

Biochemical Properties

Enzyme Kinetics

Post-translational Modifications

See Also

External Links

Summary

References

💬 Discussion